Diclofenamide is a carbonic anhydrase inhibitor used for the management of open-angle and secondary glaucoma, as well as acute angle-closure glaucoma in delayed pre-operative setting requiring a reduction in intraocular pressure.
- Mechanism
- Curator reviewed
Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow), although the mechanism by which they do this is not fully understood. Evidence suggests that HCO3- ions are produced in the ciliary body by hydration of carbon dioxide under the influence of carbonic anhydrase and diffuse into the posterior chamber which contains more Na+ and HCO3- ions than does plasma and consequently is hypertonic. Water is then attracted to the posterior chamber by osmosis, resulting in a drop in pressure.
- Primary indication
- For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressureCurator reviewed · 2 structured indications
- Formula / weight
- C6H6Cl2N2O4S2 · 305.159 g/mol (avg)
- First approval
- United States, 2012
- Also known as
- Dichlofenamide · Dichlorophenamide · Dichlorphenamide
- Brand names
Resolves to
GJQPMPFPNINLKP-UHFFFAOYSA-NSMILESNS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Diclofenamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account